[Immunoprophylaxis of superficial tumors of the bladder with interferon alfa-2b. Our experience].
OBJECTIVE
The present study was conducted to determine the usefulness of prophylactic therapy with alpha 2b interferon for superficial bladder tumors.


METHODS
Following complete TUR, alpha 2b infereron was administered to 36 patients at a dose of 50 million IU weekly for 3 months and monthly for 9 months. Patients were evaluated every 3 months on the basis of their clinical and analytical data and the cystoscopic findings.


RESULTS
Twenty-six patients completed treatment and were evaluable. The follow up and disease-free period was 25.70 months. Recurrence was observed in 38.4% of the patients and tumor progression in 3.8%.


CONCLUSIONS
Alpha 2b interferon is useful in the prevention of tumor recurrence. Its utility is similar to that of other drugs currently used.
Moyano Calvo
J L
JL
Hospital La Princesa de Madrid, Universidàd Autónoma de Madrid, España.
Teba del Pino
F
F
Sanz Sacristán
J
J
Fernández Arjona
M
M
Arellano Gañan
R
R
Rabadán Ruiz
M
M
Herrero Torres
L
L
Melón Rey
F J
FJ
Pereira Sanz
I
I
D000368:Aged; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Inmunoprofilaxis de los tumores superficiales de vejiga con interferon alfa 2b. Nuestra experiencia.